TARGIT - IORT

Intrabeam TARGIT IORT is targeted intraoperative radiotherapy treatment for breast cancer. Conceived in the UK more than 20 years ago, thoroughly tested in clinical trials, TARGIT IORT treatment is widely used to treat breast cancer patients across the world.

​

“The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment [lumpectomy and radiation therapy] at the time of her operation, with lower toxicity.”  Lancet 2014;383:603-613

​

Please visit the dedicated website for TARGIT-IORT

Information about Intrabeam TARGIT IORT

Click here for a printable information to help in a shared decision making about Intrabeam targeted intraoperative raiotherapy TARGIT IORT.

​

Intrabeam TARGIT IORT for breast cancer is clinically effective - confirmed in the TARGIT-A international clinical trial

First publication of the main results (2010)

​

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. 

The Lancet.  2010 ;376(9735):91-102.

​

5-year results and first analysis of survival (2014)

​

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. 

The Lancet. 11 November 2013. doi:10.1016/s0140-6736(13)61950-9 

Full text PDF  Podcast

​

Full 226 page report of the TARGIT-A trial of Intrabeam TARGIT IORT for HTA, NIHR, Department of Health, UK (2016)

An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). 

Health Technology Assessment 2016;20(73)

Recent peer reviewed publications are below: more are available here

• Red Journal: Meta-analyis Improved survival with targeted radiotherapy

• (This was the most downloaded paper on breast cancer in the Red Journal's Most Downloaded in 2016 list)

• Lancet: Updated meta-analysis of targeted radiotherapy confirming the survival benefit

• Lancet: A meta-analysis of the GEC-ESTRO and the TARGIT-A: 5 year data

• BMJ Open: Environmental and Social benefits of Intrabeam TARGIT IORT

• Red Journal: Better breast-related quality of life with TARGIT IORT

• NIHR Journals: Cost-Utility analysis of TARGIT IORT -  Saving £9 million/yr in thUK

• BMJ Open: Health Economics of TARGIT-IORT: Less costly for NHS

• Breast Care: A tumour bed boost after neoadjuvant chemotherapy

• Lancet: Correspondence on the IMPORT-Low trial

• BMJ Evidence Based Medicine: commentary on the IMPORT-LOW trial

• PRO: Commentary and corrections to the 2017 ASTRO APBI consensus 

Surgical technique video of TARGIT IORT for breast cancer

​

iPhone App for helping to choose TARGIT for appropriate breast cancer patients.   Android version

The TARGIT-A trial of intraoperative radiotherapy for breast cancer